For its third fiscal quarter (ending September 30), Elevance Health Inc (NYSE: ELV) has reported a 21% increase in E.P.S. from $4.38 a year ago to $5.32 in the current quarter. This performance was $0.35 better than the consensus estimate of $4.97. For the latest four quarters through September 30, E.P.S. were $24.54 compared to $27.59 a year ago — a decline of -11%.
Recent Price Action
Elevance Health Inc (NYSE: ELV) stock closed at $349.75 on 10/21/25 after a modest decline of -1.2%. Moreover, this decline was accompanied by exceptionally high trading volume at 201% of normal. The stock is unchanged during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Elevance Health has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Elevance Health has a slightly positive Appreciation Score of 64 but a very low Power Rating of 7, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment